Lynda Ouchenir1, Christian Renaud1, Sarah Khan2, Ari Bitnun2, Andree-Anne Boisvert3, Jane McDonald3, Jennifer Bowes4, Jason Brophy4, Michelle Barton5, Joseph Ting6, Ashley Roberts6, Michael Hawkes7, Joan L Robinson8. 1. Centre hospitalier universitaire Sainte-Justine, University of Montreal, Montreal, Quebec, Canada. 2. Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. 3. Montreal Children's Hospital, McGill University, Montreal, Quebec, Canada. 4. Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada. 5. London Health Sciences Centre, Western University, London, Ontario, Canada. 6. British Columbia Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada; and. 7. Department of Pediatrics, Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada. 8. Department of Pediatrics, Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada jr3@ualberta.ca.
Abstract
OBJECTIVES: The pathogens that cause bacterial meningitis in infants and their antimicrobial susceptibilities may have changed in this era of increasing antimicrobial resistance, use of conjugated vaccines, and maternal antibiotic prophylaxis for group B Streptococcus (GBS). The objective was to determine the optimal empirical antibiotics for bacterial meningitis in early infancy. METHODS: This was a cohort study of infants <90 days of age with bacterial meningitis at 7 pediatric tertiary care hospitals across Canada in 2013 and 2014. RESULTS: There were 113 patients diagnosed with proven meningitis (n = 63) or suspected meningitis (n = 50) presented at median 19 days of age, with 63 patients (56%) presenting a diagnosis from home. Predominant pathogens were Escherichia coli (n = 37; 33%) and GBS (n = 35; 31%). Two of 15 patients presenting meningitis on day 0 to 6 had isolates resistant to both ampicillin and gentamicin (E coli and Haemophilus influenzae type B). Six of 60 infants presenting a diagnosis of meningitis from home from day 7 to 90 had isolates, for which cefotaxime would be a poor choice (Listeria monocytogenes [n = 3], Enterobacter cloacae, Cronobacter sakazakii, and Pseudomonas stutzeri). Sequelae were documented in 84 infants (74%), including 8 deaths (7%). CONCLUSIONS: E coli and GBS remain the most common causes of bacterial meningitis in the first 90 days of life. For empirical therapy of suspected bacterial meningitis, one should consider a third-generation cephalosporin (plus ampicillin for at least the first month), potentially substituting a carbapenem for the cephalosporin if there is evidence for Gram-negative meningitis.
OBJECTIVES: The pathogens that cause bacterial meningitis in infants and their antimicrobial susceptibilities may have changed in this era of increasing antimicrobial resistance, use of conjugated vaccines, and maternal antibiotic prophylaxis for group B Streptococcus (GBS). The objective was to determine the optimal empirical antibiotics for bacterial meningitis in early infancy. METHODS: This was a cohort study of infants <90 days of age with bacterial meningitis at 7 pediatric tertiary care hospitals across Canada in 2013 and 2014. RESULTS: There were 113 patients diagnosed with proven meningitis (n = 63) or suspected meningitis (n = 50) presented at median 19 days of age, with 63 patients (56%) presenting a diagnosis from home. Predominant pathogens were Escherichia coli (n = 37; 33%) and GBS (n = 35; 31%). Two of 15 patients presenting meningitis on day 0 to 6 had isolates resistant to both ampicillin and gentamicin (E coli and Haemophilus influenzae type B). Six of 60 infants presenting a diagnosis of meningitis from home from day 7 to 90 had isolates, for which cefotaxime would be a poor choice (Listeria monocytogenes [n = 3], Enterobacter cloacae, Cronobacter sakazakii, and Pseudomonas stutzeri). Sequelae were documented in 84 infants (74%), including 8 deaths (7%). CONCLUSIONS: E coli and GBS remain the most common causes of bacterial meningitis in the first 90 days of life. For empirical therapy of suspected bacterial meningitis, one should consider a third-generation cephalosporin (plus ampicillin for at least the first month), potentially substituting a carbapenem for the cephalosporin if there is evidence for Gram-negative meningitis.
Authors: Eduardo Fleischer; Mark I Neuman; Marie E Wang; Lise E Nigrovic; Sanyukta Desai; Adrienne G DePorre; Rianna C Leazer; Richard D Marble; Laura F Sartori; Paul L Aronson Journal: Hosp Pediatr Date: 2019-11-05
Authors: N Caporarello; M Olivieri; M Cristaldi; M Scalia; M A Toscano; C Genovese; A Addamo; M Salmeri; G Lupo; C D Anfuso Journal: Mol Neurobiol Date: 2017-09-18 Impact factor: 5.590
Authors: Andrea T Cruz; Prashant Mahajan; Bema K Bonsu; Jonathan E Bennett; Deborah A Levine; Elizabeth R Alpern; Lise E Nigrovic; Shireen M Atabaki; Daniel M Cohen; John M VanBuren; Octavio Ramilo; Nathan Kuppermann Journal: JAMA Pediatr Date: 2017-11-06 Impact factor: 16.193
Authors: Christopher M Pruitt; Mark I Neuman; Samir S Shah; Veronika Shabanova; Christopher Woll; Marie E Wang; Elizabeth R Alpern; Derek J Williams; Laura Sartori; Sanyukta Desai; Rianna C Leazer; Richard D Marble; Russell J McCulloh; Adrienne G DePorre; Sahar N Rooholamini; Catherine E Lumb; Fran Balamuth; Sarah Shin; Paul L Aronson Journal: J Pediatr Date: 2018-10-05 Impact factor: 4.406
Authors: Marie E Wang; Mark I Neuman; Lise E Nigrovic; Christopher M Pruitt; Sanyukta Desai; Adrienne G DePorre; Laura F Sartori; Richard D Marble; Christopher Woll; Rianna C Leazer; Fran Balamuth; Sahar N Rooholamini; Paul L Aronson Journal: Hosp Pediatr Date: 2020-12-14